

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 April 2022 (28.04.2022)



(10) International Publication Number
WO 2022/084440 A2

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/46 (2006.01)
C07K 16/30 (2006.01) A61K 39/395 (2006.01)
C07K 16/32 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/EP2021/079184

(22) International Filing Date:

21 October 2021 (21.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20203110.0 21 October 2020 (21.10.2020) EP

(71) Applicant: NUMAB THERAPEUTICS AG [CH/CH];
Einsiedlerstrasse 34, 8820 Wädenswil (CH).


(72) Inventors: URECH, David; Sonnenblickstrasse 8, 8645 Jona (CH). GUNDE, Tea; Turbinenstrasse 33, 8005 Zurich (CH). SIMONIN, Alexandre; 5 Rue de l'Au, 68128 Rose-nau (FR). CHATTERJEE, Bithi; Mattenhof 33, 8051 Zurich (CH). SNELL, Daniel; Im Sunnebühl 8, 8800 Thal-wil (CH).

(74) Agent: WALLINGER RICKER SCHLOTTER TOST-MANN; VIRNEKÄS, Bernhard, Zweibrückenstraße 5-7, 80331 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: COMBINATION TREATMENT

Figure 8



(57) Abstract: The present invention relates to a pharmaceutical composition comprising a first multispecific antibody (MA1) comprising one binding domain, which specifically binds to CD137 (CD137-BD), and one binding domain, which specifically binds to PDL1 (PDL1-BD); a second multispecific antibody (MA2) comprising at least one binding domain, which specifically binds to a tumor cell associated antigen (TAA-BD), and one binding domain, which specifically binds to CD3 (CD3-BD); and a pharmaceutically acceptable carrier. The present invention further relates to a kit comprising said first multispecific antibody MA1 and said second multispecific antibody MA2. The present invention further relates to the use as well as to methods of use of said pharmaceutical composition or said kit. Finally, the present invention relates to a method for treating a patient suffering from cancer, comprising the step of administering a first multispecific antibody (MA1) comprising one binding domain, which specifically binds to CD137 (CD137-BD), and one binding

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

domain, which specifically binds to PDL1 (PDL1-BD), and a second multispecific antibody (MA2) comprising at least one binding domain, which specifically binds to a tumor cell associated antigen (TAA-BD), and one binding domain, which specifically binds to CD3 (CD3-BD).